Calarota S A, Kjerrström A, Islam K B, Wahren B
Swedish Institute for Infectious Disease Control, Microbiology and Tumor Biology Center, Karolinska Institute, SE-171 82 Solna, Sweden.
Hum Gene Ther. 2001 Sep 1;12(13):1623-37. doi: 10.1089/10430340152528129.
DNA plasmid immunization has the important advantage over traditional vaccines of making it possible to combine selected genes into one vaccine. The efficacy of a combination of DNA plasmids encoding the nef, rev, and tat HIV-1 regulatory genes in inducing cellular immune responses was analyzed in asymptomatic HIV-1-infected patients. Patients initially selected for having low or no detectable immune responses to Nef, Rev, or Tat antigens developed MHC class I-restricted cytolytic activities as well as enhanced bystander effects. The induction of memory cells against target cells infected with the whole HIV-1 genome was analyzed by using a pseudovirus HIV-1/murine leukemia virus (MuLV), and target cells infected with vaccinia virus carrying the respective gene. The most remarkable change observed after immunization with the gene combination was an increase in cytotoxic T lymphocyte (CTL) precursors to target cells infected with the whole HIV-1 genome. Infection by the pseudotype HIV-1/MuLV virus should result in a multitude of HIV-1 peptides presented on the target cell surface, representative of the in vivo situation. An in vitro assessment of the expression of the single and combined gene products showed that this was consistent with the induction of CTL responses in vivo. No clinical advantage or adverse effects were noted. Therapeutic effects of such immunization may become measurable by structured therapy interruption.
与传统疫苗相比,DNA质粒免疫具有重要优势,即能够将选定的基因组合到一种疫苗中。在无症状的HIV-1感染患者中分析了编码HIV-1调节基因nef、rev和tat的DNA质粒组合在诱导细胞免疫反应方面的功效。最初被选定为对Nef、Rev或Tat抗原检测不到免疫反应或免疫反应较低的患者,产生了MHC I类限制性溶细胞活性以及增强的旁观者效应。通过使用假病毒HIV-1/鼠白血病病毒(MuLV)以及感染携带相应基因的痘苗病毒的靶细胞,分析了针对感染完整HIV-1基因组的靶细胞的记忆细胞诱导情况。用基因组合免疫后观察到的最显著变化是针对感染完整HIV-1基因组的靶细胞的细胞毒性T淋巴细胞(CTL)前体增加。假型HIV-1/MuLV病毒感染应导致多种HIV-1肽呈现在靶细胞表面,这代表了体内情况。对单一和组合基因产物表达的体外评估表明,这与体内CTL反应的诱导一致。未观察到临床优势或不良反应。通过结构化治疗中断,这种免疫的治疗效果可能变得可测量。